A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer
Antineoplastic Combined Chemotherapy Protocols
Head and Neck Neoplasms
The phase 2 recommended dose was 7.5 mg daily for everolimus plus cisplatin and docetaxel (both at 75 mg/m(2) on day 1 of a 21-day cycle) given with pegfilgrastim support.
PubMed Central ID
Digital Object Identifier (DOI)
Additional Document Info
has global citation frequency